← All trials
NCT04202068
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 3, 2015
- Primary completion
- May 3, 2016
- Completion date
- May 30, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 113
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Xiangbei Welman Pharmaceutical Co., LtdLead sponsor
- Fujian Medical UniversityOverall official - principal investigator
- Yanbian UniversityOverall official - principal investigator
- Shanghai Dermatology HospitalOverall official - principal investigator
- People's Hospital of QuzhouOverall official - principal investigator
- Hangzhou Third HospitalOverall official - principal investigator
- The Central Hospital of Shanghai Minhang DistrictOverall official - principal investigator
- People's Hospital of Shanghai Pudong New AreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.